Iron removal by the chelating-agent deferoxamine (DFO) arrests cell cycle progression of activated human T cells in late G1 phase, before the G l / S border. The effects of the drug on molecules that regulate progression through the cell cycle were defined. DFO (10 pmol/L) inhibited induction of transcription of the cdc2 gene, but had no effect on accumulation of cdk2, cdk4, or interleukin (IL)-2 transcripts. No detectable ~3 4~" protein accumulated, but synthesis of the p33-protein was begun. It accumulated to normal levels during the first 20 to 30 hours of incubation in the presence of DFO. Furthermore, ~3 3~~ was activated as an H I histone kinase. As active p33-primarily represents complexes of the p33 protein with cyclin E or cyclin A, the effects of DFO T HE DRUG DEFEROXAMINE (DFO), which is frequently used to reduce iron content in individuals with an overabundance of the essential can also potentially result in undesirable effects on cells of the immune ~y s t e m .~.~ It has also been observed that iron depletion, through the use of chelators, can quickly inhibit the growth of some cell types, with lymphocytes and cells of neuronal origin being especially ser~sitive.~"' To further elucidate the role of iron in cell cycle progression, the point of action of the chelator has been defined.
Iron removal by the chelating-agent deferoxamine (DFO) arrests cell cycle progression of activated human T cells in late G1 phase, before the G l / S border. The effects of the drug on molecules that regulate progression through the cell cycle were defined. DFO (10 pmol/L) inhibited induction of transcription of the cdc2 gene, but had no effect on accumulation of cdk2, cdk4, or interleukin (IL)-2 transcripts. No detectable ~3 4~" protein accumulated, but synthesis of the p33-protein was begun. It accumulated to normal levels during the first 20 to 30 hours of incubation in the presence of DFO. Furthermore, ~3 3~~ was activated as an H I histone kinase. As active p33-primarily represents complexes of the p33 protein with cyclin E or cyclin A, the effects of DFO T HE DRUG DEFEROXAMINE (DFO), which is frequently used to reduce iron content in individuals with an overabundance of the essential can also potentially result in undesirable effects on cells of the immune ~y s t e m .~.~ It has also been observed that iron depletion, through the use of chelators, can quickly inhibit the growth of some cell types, with lymphocytes and cells of neuronal origin being especially ser~sitive.~"' To further elucidate the role of iron in cell cycle progression, the point of action of the chelator has been defined.
In earlier work, we demonstrated that iron depletion arrests the growth of activated T lymphocytes before S phase entry.'"13 Growth arrest could be seen in vitro with a dose of DFO (10 pmol/L) that is achieved in humans in clinical application^,'^.^^ a fact which may explain its immunosuppressive effects. As iron is required for the activity of ribonucleotide reductase,16 it at first seemed likely, as we proposed earlier,7 that iron depletion affected cell cycle progression by blocking activity of this key enzyme. However, we and others noted that iron-chelating agents, such as DFO or mimosine, in fact, arrested cells at a point in G1 phase, demonstrably earlier than the GUS bo~ndary,""~.'~ that can be defined using the agent aphidicolin, which directly binds to and inhibits DNA polymerase.'*~19 As transferrin receptor mRNA becomes detectable as early as 1 hour after stimula-on these cyclins were examined. Although the induction of synthesis and early accumulation of cyclin E and cyclin Eassociated kinase activity appeared normal, the appearance of cyclin A and cyclin A-associated kinase activity were inhibited by DFO. However, the production of cyclin A mRNA appeared to be normal in the presence of DFO. A major effect of DFO in blocking cell cycle progression may be mediated through inhibition of the appearance of cyclin A protein and, therefore, a major component of ~3 3~~ activity. The results also indicate that the p33Ddm/cyclin E activity produced in the presence of DFO was not sufficient for completion of the G1 phase of the cell cycle. 0 1995 by The American Society of Hematology.
tion of resting T cells and reaches a maximal level about 5 hours later, well before maximal expression of L -2 receptor mRNA," a requirement for iron in the first G1 phase of activated T cells was not unexpected. We, therefore, initiated studies to determine the effects of DFO on cell cycle regulatory events known to occur in mid-to-late G1 phase of the T-cell cycle.
We previously characterized the DFO arrest point with respect to several molecular events, using normal human T lymphocytes activated to enter the cell cycle in vitro.''"3 In the presence of DFO, the cellular RNA content accumulated to an amount less than that characteristic of late G1 phase. The synthesis of the key cell cycle regulatory kinase, ~34'~"', which normally begins just before S phase entry, was inhibited; and the p1 loRb protein, which plays a role in G1 phase progression, was only partially phosphorylated. In additional studies, we showed that treatment of a neuroblastoma cell line with DFO inhibited normal increases in the cellular content of ~3 4 "~" protein and kinase activity."
The chain of events that occurs throughout G1 phase in animal cells has been defined in some detail (reviewed by Reed," and Shed'). Of major importance has been the discovery that the ~3 4 "~" kinase is but one member of a family of kinases, each of which, complexed with an appropriate cyclin molecule, appears to play a particular role in cell cycle Using this new information, we have further defined the point of DFO-induced cell cycle arrest in mitogen-stimulated human lymphocytes. It is shown that iron chelation inhibits transcription of the cdc2 gene but has little or no effect on expression of the cdk2 gene. As shown elsewhere, activation of the cdk2 and cdc2 genes normally occurs at about 8 hours (in early G1 phase) and 24 hours (just before S phase entry), respectively, after activation of human T cells. 1327~28~28a In activated human T cells, the products of these genes, the p33'"' and ~34'~'' kinases, are first detectable as active enzymes in mid-G 1 phase and at mitosis, respectively.2Ra Appearance of ~3 3 '~~' kinase activity occurs in two stages, with a modest increase occurring throughout late G1 phase and a more dramatic increase (about 10-fold higher) beginning after entry into S phase. The appearance of this second wave of activity is markedly reduced by iron depletion. The first component, due to a complex of ~3 3 '~~' and cyclin E, appears in nearly normal amounts and with normal kinetics. However, the complete inhibition of cyclin A synthesis, combined with a block to the further S-phaseassociated accumulation of the ~3 3 '~ and cyclin E proteins, prevents normal induction of the second wave of ~3 3~~ activity.
The system of DFO-arrested T cells thus permits examination of the differential roles and effects of the cyclin E-and cyclin A-associated p33cdk2 kinases. Furthermore, as overproduction andor activation of cyclins and cyclin-dependent kinases has been increasingly observed in certain tumors and tumor-derived cell line^,"*'^-^^ the possibility of using ironchelating agents to target cells with such aberrations is raised.
MATERIALS AND METHODS
Cell preparation and culture. Peripheral blood T cells isolated from healthy volunteers were used in all experiments. Mononuclear cell suspensions were prepared by Ficoll-Hypaque gradient centrifugation, and T cells (EC) were obtained by E-rosette enri~hment.3~ This population contained greater than 95% T cells as determined by immunofluorescence with anti-CD3 antibody. Cells were cultured in RPM1 medium containing 10% (voVvol) fetal calf serum and 2 mmoVL glutamine. When using normal lymphocytes, experiments are routinely repeated at least three times using cells from different donors to establish the generality and reproducibility of the findings. Representative results are presented in the figures. T cells were activated by addition of phorbol dibutyrate (PDB; 10 nmoVL) and ionomycin (0.5 pmol/L). PDB, obtained from Sigma (St Louis, MO), was dissolved at a concentration of IO-' molL in dimethyl sulfoxide. Ionomycin, obtained from Calbiochem (San Diego, CA) was prepared as a 5 mmol/L stock solution in dimethyl sulfoxide. DFO was obtained from Ciba-Geigy (Mississauga, Canada) and prepared as a stock solution in distilled water at a concentration of 200 mmofi. Metabolic labeling of cellular proteins was performed by preincubating cells in methionine-free medium containing dialyzed fetal calf serum for 30 minutes, adding 150 pCi/mL of %methionine (specific activity, 1,200 Ci/mmol; Dupont NEN, Wilmington, DE), and incubating for the times indicated.
Simultaneous pow cytometric determination of DNA and ~3 4 '~' ' content The method described by Takase et a135 was used. After a 60-minute fixation with 70% ethanol at 4"C, cells (about lo6) were pelleted and washed. After a 5-minute incubation in 250 p1 of phosphate-buffered saline (PBS) containing 0.5% Tween 20, 0.5% bovine serum albumin, and 1.5% human y-globulin (Sigma) at room temperature, 2 pg of mouse monoclonal antihuman ~3 4 "~' antibody (Zymed, San Francisco, CA) was added, and the mixture was incubated at 4" for 120 minutes. This antibody, directed against a peptide comprising the C-terminal 15 amino acids does not appear to crossreact with any of the other known cdks present in T cells (Lucas et al, unpublished data, June 1994). The cells were washed and further treated with 3 p1 of a fluorescein isothiocyanate (F1TC)-conjugated F(ab')* fragment of affinity-purified sheep antimouse immunoglobulin (Sigma) at 4°C for 60 minutes. The cells were washed and then incubated with 0.5 mL of 0.25 mg/mL ribonuclease (type 111-A, Sigma) in phosphate-buffered saline (PBS) at 37°C for 10 minutes. The cell suspension was mixed with 0.5 mL of a solution of propidium iodide (50 p g / d in PBS) and, after 60 minutes, was analyzed using a flow cytometer (EPICS Profile; Coulter, Hialeah, K), collecting green fluorecence (520 to 540 nm) and red fluorescence (greater than 600 nm) in linear scales with 488 nm excitation.
Northern blot analysis. mmoVL Tris-HC1 pH 7.4,50 mmol/L NaCl, 0.5% sodium deoxycholate, 2% Nonidet P-40, 0.2% SDS, 1 mmoVL phenylmethylsulfonyl fluoride (PMSF), 50 pg/mL aprotinin, 50 pmol/L leupeptin, and 100 pmovL sodium orthovanadate." After removal of cellular debris by centrifugation, lysates were prepared for electrophoresis, and polyacrylamide gel electrophoresis in the presence of SDS (SDS-PAGE) was performed as described by Laemmli!' After electrophoretic transfer of proteins to nitrocellulose membranes and blocking of the filters with a solution containing bovine serum albumin:' filters were incubated with the appropriate primary antibody, as follows: for detection of ~34'~'', a mouse monoclonal antibody directed against a peptide comprising the C-terminal 15 amino acids of the protein (Zymed, San Francisco, CA); for p33"=, a rabbit polyclonal antibody directed against a peptide comprising the C-terminal 12 amino acids of the protein (UBI, Lake Placid, NY); for cyclin A, a rabbit polyclonal antibody directed against a peptide comprising a C-terminal portion of the protein (residues 359-432; UBI); for cyclin E, a mouse monoclonal antibody (HE 12) prepared using recombinant cyclin E protein (Pharmingen, San Diego, CA); and for pllORb, a mouse monoclonal antibody (1 F8) prepared using recombinant Rb protein (Santa Cruz Biotech, Santa Cruz, CA). Proteins were detected by an enhanced chemiluminescence (ECL) method using reagents and procedures provided by Amersham International ( A rlington Heights, IL). The secondary antibodies used were either a sheep antimouse or donkey antirabbit antibody, linked to horseradish peroxidase.
Immunoprecipitation of metabolically (3SS-methionine) labeled proteins. After labeling of cells, as described above, they were collected by centrifugation and washed twice with cold PBS. Cells were disrupted by a 15-minute incubation in RIPA buffer (150 mmoV L NaCl, 50 mmoVL Tris pH 7.4, 0.1% Triton X-100, and 0.5% sodium deoxycholate) containing 1 mmoVL PMSF, 10 pg/mL leupeptin, 20 pg/mL aprotinin, 0.1 mmoUL sodium orthovanadate, and 50 mmolfL sodium fluoride?' Cell lysates were clarified by centrifugation, and supernatants were incubated with Protein G coupled to Sepharose beads (Zymed) for 30 minutes at 4°C. After removal of the Protein G-beads, supernatants were incubated with the appropriate specific primary or control antibody for 2 hours at 4°C. For detection of the ~3 3 '~~ protein, the precipitating antibody used was the rabbit polyclonal antibody described above; control antibody was IgG obtained from an irrelevantly immunized rabbit. A 10-pg amount of primary antibody was used for an extract prepared from IO' cells, an amount determined to result in near complete recovery of the For personal use only. on November 11, 2017. by guest www.bloodjournal.org From antigen. Immunocomplexes were recovered by binding to protein G-beads. Complexes were washed five times with RIPA buffer before being suspended in electrophoresis sample buffer.";" Samples were heated for 5 minutes at 9 0 T , and beads were pelleted by centrifugation and discarded. The denatured proteins were resolved by SDS-PAGE and visualized by fluorography."."
Immunoprecipitation of active cyclin-dependent kinase/cyclin complexes. For isolation of active complexes for in vitro kinase assays, the method of Howe et was used, with some modifications. Cells (2 X IO6 to S X 10') were washed with PBS and then lysed in a buffer containing S0 mmol/L Tris-HC1 pH 7.4, S mmol/ L EDTA, 250 mmol/L NaC1, 1 mmol/L PMSF, 50 pg/mL aprotinin, 50 pmoVL leupeptin, 100 pmol/L sodium orthovanadate, and 0.1 % Nonidet-P40 (NP-40 lysis buffer). Complexes were precipitated with the same antibodies used for immunoblotting, except in the case of cyclin E, for which the mouse monoclonal antibody HE 67 (Pharmingen) was used. Optimal amounts of primary antibodies were used, as determined by prior immunoprecipitation experiments using radiolabeled (35S-methionine) protein extracts. Complexes were recovered by precipitation with protein G chemically bound to Sepharose beads (Zymed).
Enzymatic assay for cdk activity. The complexes, prepared by immunoprecipitation, were washed first with the NP-40 lysis buffer and then with a solution containing S0 mmolL Tris-HC1 pH 7.4, 10 mmoUL magnesium chloride, and 1 mmol/L dithiothreitol. They were incubated in a kinase reaction buffer (25 p L per sample) containing S0 mmoVL Tris-HC1 pH 7.4, 10 mmolL magnesium chloride, 1 mmolL dithiothreitol, 80 pmoVL adenosine triphosphate (ATP), 10 pg of histone H1 (Boehringer Mannheim, Indianapolis, IN), and 40 pCi of [y-32P]-ATP at 30°C for 10 minutes:'
All reactants were in excess, and the reactions were stopped by addition of an SDS-containing electrophoresis sample buffer while in a linear range of reaction. After heating at 90°C for S minutes and then cooling, the protein G-immunobeads were pelleted by centrifugation, and proteins in the reaction mixtures were resolved by SDS-PAGE. The histone H1 band was visualized by a brief staining of the gels with Coomasie Blue (R-250) in fixative (10% acetic acid/40% methanoUSO% water). The gels were then dried, and the labeled histone bands were detected by autoradiography. The Coomassie-stained histone bands were excised from the dried gels and quantitated by scintillation counting. Unless noted in the text, values were corrected for nonspecific activity, which was determined from duplicate samples in which the primary antibody step was omitted. As comparisons are made between levels of activities obtained using complexes immunoprecipitated using different antibodies (eg, cyclin A-v cyclin E-associated activities), data are expressed as the percentage of maximal activity obtained with a particular antibody. Because many factors associated with the reactions, for example, the differential effects of the antibodies on reactions performed by particular cdk/ cyclin complexes, are unknown, direct comparisons of the absolute values (counts per minute incorporated into the H1 histone substrate) are not made.
RESULTS
Effects of DFO on cell cycle progression in normal human T lymphocytes. As shown previously," dual flow cytometric analysis of DNA and RNA contents have permitted a detailed delineation of the kinetics of cell cycle progression in normal human T lymphocytes. In brief, it was shown that T cells activated with the potent combination of PDB and ionomycin (PDB/I) rapidly enter the G1 phase of the cell cycle, as indicated by increasing content of RNA. S-phase entry, indicated by increased DNA content, begins at about 30 hours after activation. By performing flow cytometric analysis of cells that have been activated with PDB/I and then accumulated about the G 2 M border with demecolcine, it has been estimated that 80% to 90% of activated T cells enter and progress through the cell cycle4j (Takase et al, unpublished results, April 1994). DFO has been shown to arrest T-cell proliferation before S-phase entry. Determinations of RNA content indicated that this point occurred in mid-to late G1 phase, as cells possessed an overall RNA content significantly lower than T cells poised to enter S phase."
T-cell progression and the effects of DFO on the cell cycle were further delineated using a new method for the simultaneous determination of DNA and ~3 4 '~" ' cellular content~.~' As shown in Effects of DFO on expression of T-cell cycle regulatory genes. In previous reports,'o"3 we showed that DFO inhibited cell cycle progression at a point in late G1 phase, before the GUS-phase transition, which was earlier than and distinguishable from the arrest point induced by either aphidicolin or hydroxyurea. T lymphocytes arrested by DFO contained no detectable p34'd'2 protein, a protein whose synthesis begins just before and independently of S-phase e n t~y .~' .~~ In the first cell cycle of activated human T lymphocytes, the cdk2 and cdc2 genes are first expressed beginning at about 8 and 24 hours after activation, r e s p e c t i~e l y .~~~~~~~~" AS shown in Fig 2, accumulation of transcripts of these two genes shows a differential sensitivity to the chelating agent. The steady-state levels of cdk2 mRNAs accumulated are the same in the presence or absence of the drug, even at a concentration of 100 ymol/L. Accumulation of cdc2 mRNA, on the other hand, is almost completely suppressed by DFO, even at the low dose of 10 PmoVL. As shown in Fig 3, expression of the cdk4 and ZL-2 genes, which normally is first detected within 3 to 4 hours after a c t i v a t i~n ,~"~~~"~~~~~~ was also not affected by DFO.
Effects of DFO on accumulation of cell cycle regulatory proteins. Stimulation of T cells with PDB/I induces a large portion of the cells to synchronously enter the cell These proteins begin to increase in amount in
For also demonstrated in Fig 4 that normal levels of the ~3 3 '~'~ and cyclin E proteins accumulate in T cells that are activated in the presence of DFO and an excess of iron. Also, it was determined that phosphorylation of the pl loRb protein (shown by the appearance of the slower mobility forms of the protein) was initiated in the presence of DFO (Fig 4) . However, levels of phosphorylation of pl IORh achieved in the presence of DFO were characteristic of those normally seen after about 30 hours after activation; attainment of the normal pattern of hyperphosphorylation, characteristic of S-phase entry and progression,".'~.5".4' was partially suppressed. Also shown in Fig 4, addition of excess iron to the cultures almost completely restored the normal pattern of accumulation and phosphorylation of p1 IORh, indicating that the effects of DFO were, indeed, due to chelation of the metal.
Effects of DFO on metabolism of the p3.Yd2 protein. The results described above indicate that the induction of cdk2 gene expression and p3Ydk2 protein synthesis occurred normally in the presence of DFO and place the point of arrest in late GI phase, before the first appearance of the ~34'~'' and cyclin A proteins, which normally begin just before the Gl/S-phase transition. The exact role(s) of the p3Y"' kinase in cell cycle progression is still unclear. It has been proposed that the p3Ydk2 kinase, which has been found to be associated with both cyclin A and cyclin E, may regulate passage LUCAS ET AL through the so-called "restriction point," entry into S phase, and/or progression through S pha~e.'~..'~.~'.~"-~'.~~.~' A possible role for p3Ydk2 at the G2/M phase transition has also been disc~ssed.~' As DFO arrested cell cycle progression in late G1 phase, apparently without suppressing the initial production of the ~33'"'' protein, the effects of the drug on this protein were examined in more detail.
First, as shown in Fig SA, the levels of p3Ydk2 protein accumulated in the presence or absence of DFO were compared. In this experiment, the ~33'~'' protein was prepared by immunoprecipitation. After resolution of proteins by electrophoresis, the protein was detected by immunoblotting. As shown by comparison of lanes 1 and 2 in Fig 5A, As noted above, levels of cdk2 mRNA appeared to be normal in cells activated in the presence of DFO, even as late as 48 hours of incubation. To determine whether the decreased accumulation of the protein was due to decreased synthesis or enhanced degradation of the protein, the follow- ing experiments were performed. First, activated T cells incubated in the presence or absence of DFO were metabolically labeled with "S-methionine at 18 to 25 and 26 to 33 hours after stimulation. The ~3 3 '~~' protein was isolated by immunoprecipitation and then detected by autoradiography after gel electrophoresis. As shown in Fig 5B, the extent of incorporation into the protein was nearly identical at the earlier time point in the presence (lane 2) or absence (lane 3) of DFO. By the later time point, the extent of incorporation was clearly reduced in the DFO-treated cells (lane 5) as compared with control cells (lane 6). suggesting that the rate of synthesis of the protein was decreased by this time point. Finally, to ascertain whether or not the decreased accumulation of the protein could be due at least partly to enhanced protein degradation induced by the drug, cells were labeled with "S-methionine from 42 to 45 hours after activation in 2273 the absence or presence of DFO. A portion of each culture was harvested at 45 hours. The remaining cells were washed free of the radioisotope, and portions were incubated for an additional 2 or 4 hours in normal growth medium. The p3Ydk2 protein was isolated from the six samples and visualized by autoradiography after electrophoresis. As shown in Fig 5C, the amount of label incorporated during the labeling period was, as expected, somewhat reduced in the presence of DFO (lane 4) as compared with the control cells activated in the absence of the drug (lane 1). However, the kinetics of decay appeared to be essentially the same in the presence or absence of DFO. A slight loss of radioactivity associated with ~3 3 '~~~ was detected by 2 hours (lanes 2 and 5 ) after the labeling period and became more pronounced by 4 hours (lanes 3 and 6) . It appeared that the protein was a relatively long-lived one in the absence or presence of DFO. No rapid or dramatic degradation of p3Ydk2 occurred in the presence of the drug, supporting the notion that the increased synthesis normally occumng as cells entered and progressed through S phase was, indeed, curtailed.
The effects of DFO on HI histone kinase activities in T cells. The levels of H1 histone kinase activity due to ~34'~'' and ~3 3 '~~~ after T-cell activation in the presence or absence of DFO were compared. In the experiment shown in Fig 6 , kinase activities associated with specific immunoprecipitates of the two kinases were measured at 55 hours after stimulation. At this late time point, normal levels of activity due to both kinases were very high. As expected considering its inhibitory effect on the appearance of the protein, DFO almost completely prevented the appearance of ~34'~'' kinase activity. Activity due to ~3 3 '~~' was also substantially reduced, to about 8% of its control level, as determined using the extract prepared from cells activated in the absence of the drug. However, that this represents a substantial level of activity above background control levels or the low residual level of ~34'~'' activity is apparent from a comparison of the two autoradiograms presented as insets in Fig 6. As DFO appeared to inhibit the late accumulation of p3Ydk2, but not its initial synthesis, ~3 3 '~~~ activity was next measured at earlier times after activation in the presence or absence of the drug. In these experiments, active cyclid ~3 3 '~~~ complexes were isolated by immunoprecipitation from cells activated in the presence or absence of DFO. Histone H1 kinase activities were determined using the in vitro kinase reaction method described above. The normal kinetics of activation of ~3 3 '~~' after T-cell stimulation occurs in two distinguishable phases (Fig 7, solid bars) .2s" Activity is first detectable at about 15 to 20 hours after stimulation. It increases slowly for up to 30 hours, until the Gl/S-phase transition, reaching about 10% of subsequent maximal levels. After entry into S phase, the second phase of activation, marked by a rapid 10-fold increase in activity, begins. In the presence of DFO (Fig 7, open bars) , the initial phase of activation of the kinase was observed; the levels of ~3 3~~' '~ activity present at 20 hours were nearly the same in cells activated in the presence or absence of DFO. By 30 hours, however, an inhibitory effect of the drug became evident, and the dramatic 10-fold increase associated with S-phase entry and progression was nearly completely inhib- It has been shown in several cell systems that the ~33'~'' kinase forms active complexes primarily with two cyclins, and that the cyclin Eassociated activity precedes cyclin A-associated activity in the GI phase of the cell ~y~l e .~"~"~~'~'~ The effects of DFO on cyclin E-and A-associated HI histone kinase activities were, therefore, examined, as shown in Fig 8 . Cyclin Eassociated activity was first detected in mid-GI phase (about 20 hours): a larger increase, although not as great as that seen for overall ~3 3 " '~' activity, was seen after S-phase entry. As for initial overall p33"Ik2 activity, the initial appearance of cyclin E-associated activity was refractory to DFO. Even at 30 hours after activation, inhibition of cyclin E-associated activity was modest: the level of cyclin E-associated activity 1 p33cdk2 degradation detected in S phase was also only partially (about 40%) inhibited by DFO. In contrast, the appearance of cyclin Aassociated activity (Fig 8) was completely inhibited by DFO, consistent with observations that the drug prevents the appearance of cyclin A protein. It is also shown that a low level of cyclin A-associated activity appears at about 30 hours after stimulation (in the absence of DFO) and increases more dramatically as cells enter S phase. Thus, p33'"'' activity seen before about 30 hours appears to be due primarily to cyclin E/~33'~~', and its synthesis and activity are largely resistant to the effects of DFO. Beginning at about 30 hours. ~3 3 " '~' activity is due in some part to cyclin A/p33"'k2. As cyclin A synthesis is completely inhibited, this component of ~33'~'' activity does not appear and cell cycle progression is halted. However, the possibility that the modest decrease seen in GI phase cyclin E-associated activity also plays some role in the DFO-induced arrest is not precluded by the present data.
Eflects of DFO on occumulntion of cyclin E and cvclin A mRNAs.
To further analyze the level at which DFO exerted its inhibitory effect on cyclin A protein accumulation, the levels of cyclin A and cyclin E mRNAs were compared. As shown in Fig 9, cyclin E mRNA was easily detected at 24 and 48 hours after T-cell activation. As expected based on the observation that cyclin E protein accumulation proceeded fairly normally during this period (Fig 4) , DFO had little effect on cyclin E mRNA levels. Cyclin A mRNA levels, which could also be readily detected at both 24 and 48 hours after activation, appeared only slightly depressed in 1 and 2) or 40 (A, lanes 3 through 5) hours after incubation. The ~3 3 '~~ protein was isolated by immunoprecipitation. After resolution of proteins by gel electrophoresis, the ~3 3~~" protein was visualized by immunoblotting. (B) The rates of synthesis of the ~3 3~" protein in the presence and absence of DFO were compared. T cells were activated with PDB/l in the absence (B, lanes 1, 3,4, and 6) or presence (B, lanes 2 and 5) of DFO. Cultures were metabolically labeled with 35S-methionine from 18 t o 25 (B, lanes 1 through 31 or 26 t o 33 (B, lanes 4 through 61 hours of incubation. The ~3 3~~" protein was prepared by immunoprecipitation IB, lanes 2,3,5, and 6) with specific rabbit polyclonal antibody and detected by fluorography after resolution of protein by gel electrophoresis. Control radiolabeled samples were incubated with rabbit antiserum from a nonimmunized animal instead of the specific a n t i -~3 3~~" antiserum and were similarly processed (B, lanes 1 and 4) t o facilitate identification of the ~3 3 '~" protein band, which is indicated in the figure. (C) The degradation of the ~3 3 '~~' protein in the presence and absence of DFO were compared. T cells were activated with PDB/I in the absence (C, lanes 1 through 3) or presence (C, lanes 4 through 61 of DFO and metabolically labeled with "S-methionine at 42 t o 45 hours of incubation. Samples were harvested immediately after labeling (C, lanes 1 and 41 and at 2 (C, lanes 2 and 5) and 4 (C, lanes 3 and 6) hours after removal of the "S-methionine from the cultures by extensive washing. The ~3 3 '~" protein, indicated in the figure, was isolated by immunoprecipitation and visualized by fluorography after resolution of proteins by gel electrophoresis, as described above. Protein extracts prepared from equal numbers of cells were loaded in the lanes.
For the presence of DFO (Fig 9) . despite the fact that no cyclin A protein is present in DFO-arrested T cells (Fig 4) . At 48 hours after stimulation, there appeared to be slightly more cyclin E and cyclin A mRNA in the absence of DFO (lane 4). However, as demonstrated in the bottom panel of Fig 9, which shows the ribosomal RNAs present in the gel, it appears that somewhat more overall RNA was applied to the lane showing RNA from cells activated in the absence of DFO (lane 4).
DISCUSSION
Recent analysis of the cell cycle of mammalian cells has shown that major cell cycle transitions are regulated at least in part by a family of serine-protein kinases, called cyclindependent kinases, and the cyclin molecules with which they ~3 4 '~~' ) , complexed with cyclins of the B family, plays a role in regulating entry into mitosis.'R"' Much evidence suggests that a second member of the kinase family, ~33'~'*, complexed with cyclins of the A and/or E families, regulates earlier, important cell cycle regulatory events: committment to cell division, occurring in late GI phase (at a putative start or restriction point), the GUS phase transition, and, perhaps, even passage through S phase."~'9~"~4"4x~''~s7 However, the fact that no in vivo substrates for these cdkkyclin complexes have been definitively identified (although several have been proposed), combined with the apparent promiscuity of the enzyme in combining with cyclins of many families including not only A and E cyclins, but also mem- In the present study, the effects of DFO on proliferation of normal human T cells were defined in terms of the molecules involved in GI-phase progression and S-phase entry. Inhibition of cell cycle progression with DFO arrested the cells at a point in G1 phase before the appearance of cyclin A. However, the G1 phase-associated synthesis of cyclin E and p33""' and their assembly into a complex with enzymatic activity proceeded almost normally. These results suggest that the p3Ydk'/cyclin A complex is needed for completion of the GI phase of the cell cycle. However, the possibilities that the early cyclin E-associated activity produced in the presence of DFO, although little affected, is still insufficient for completion of G I -phase or that still other, as yet unidentified, cell cycle regulatory events are also inhibited have not been excluded. For example, whether or not DFO has an effect on the synthesis and/or activities of low-molecular- weight proteins such as p21 and p27, which can inhibit the activity of cyclin-dependent kinase^,^'.^' remains to be determined. As the synthesis of DNA is blocked, because of inhibition of ribonucleotide reductase, many events associated with normal progression through S phase are also blocked. These events include the complete S phase-associated increases in (1) cyclin E and p33-protein levels, (2) cyclin E-associated kinase activity, and (3) complete hyperphosphorylation of the pllORb protein. As shown in Figs 4, 7, and 8, all of these events are dampened. It is suggested, however, that these events are subsequent or secondary to the late GI-phase block described here and in previous rep o r t~. " -~~ As events associated with S-phase progression, including the dramatic increase in p33'"%yclin E activity, were depressed by DFO, a role for this latter complex in S phase progression is not ruled out by the data. In fact, the dramatic increase seen as cells enter S phase make such a role likely and supports a model in which multiple cdklcyclin complexes function at particular phases of the cell cycle.
The exact mechanism by which iron depletion results in the lack of appearance of cyclin A protein remains to be determined. As we showed previously, cyclin A synthesis is initiated before S-phase entry in normal human T cells.4" Initiation of its synthesis is independent of S-phase entry, and it is accumulated to aberrantly high levels in cells that are blocked at the GUS interface by treatment with aphidicolin. We have, therefore, begun to examine events leading to production of cyclin A, and the effects of DFO on these events. Surprisingly, it was found that levels of cyclin A mRNA were little affected by the presence of DFO. Because the rate of synthesis of the ~33'"' protein (Fig 5) and the kinetics of accumulation of cyclin E protein (Fig 4) are proceeding nearly normally during DFO arrest, when no detectable cyclin A protein is accumulated (Fig 4) , the possibility arises that DFO is preferentially inhibiting the translation of certain mRNAs. Roles for iron in the translation of proteins have been demonstrated and discussed previo u s l~.~"~~ Alternatively, DFO may be inhibiting the appearance of cyclin A mRNA in the cytoplasm. A possible role for iron in mRNA transport has also been recently noted. 74 Lastly, it is possible that the stability of any cyclin A protein that is synthesized is greatly reduced in the presence of the drug. All of these possibilities are amenable to direct experimental analysis, as is now in progress. Finally, it should be noted that synthesis of the ~3 4 "~' protein is also prevented by treatment with DFO. However, since this protein is not activated as a kinase until near the G2M-phase border in the first cycle of normal T cells induced to enter the cell cycle:' " it is unlikely that inhibition of its synthesis is responsible for the arrest in late G1 phase observed here. Now that the block to cyclin A production in DFO-arrested T cells has been identified, more incisive molecular analysis of the phenomenon, both in normal T cells and in cultured cell lines, will be possible. Such studies will include determination of the mechanism by which cyclin A absence affects subsequent events in T-cell cycle progression. To this end, we have begun an examination of how the absence of cyclin A protein in DFO-arrested cells affects the forms of the E2F transcription factor that are present. E2F, which can be found in complexes with cyclin A and cyclin E, appears to be needed in a free form for activation of transcription of genes necessary for S phase (reviewed by N e~i n s~~) .
Gel shift analysis has yielded the expected result that DFO inhibits the appearance of the cyclin A-containing form of E2F complex (Terada et al, unpublished results, February 1994) . However, the effects of this on the relative amounts of other forms of E2F and on transcription of E2F-regulated genes require further study.
Since our initial reports on the inhibition of accumulation of ~3 4 "~~~ in normal T cell^'^.'^ and neuroblastoma cells," the effects of another iron chelator, mimosine, on HI histone kinases has been described. 76 In contrast with results presented here, it was noted that the addition of mimosine to human fibroblasts entering the cell cycle resulted in essentially complete inhibition of total cdk2 activity. However, it should be noted that, whereas our studies used the minimal dose (10 pnoVL) of DFO needed for effective inhibition of S-phase entry, the latter study used a concentration of mimosine of 300 pmolL. Determination of whether or not the observed differences seen are due to different concentrations of agents, to different cell types, or to actual differences in T cells were activated with PDB/I in the absence 1 .) or presence IO) of DFO and harvested at the times indicated. Cyclinlcdk complexes were isolated by immunoprecipitation with antibody specific for either cyclin E or cyclin A and then assessed for H1 histone kinase activity, as described in Materials and Methods. Activity is shown as percent of maximal activity, which is taken as the value associated with the samples isolated at 40 hours after stimulation, in the absence of DFO. Because different specific antibodies are used for isolation o f complexes using antibodies t o cyclin A, cyclin E, or the kinases (as in Figs 6 and 7) . direct comparisons of absolute values are not made. Note that some different time points were used for each analysis, because cyclin E-associated activity can first be detected at about 15 t o 20 hours, whereas cyclin A and its associated activity are not seen until later (about 30 hours). The numbers within the open boxes in the left panel show the percent inhibition of the cyclin E-associated activity in the DFO-treated samples, as compared with the untreated activated cells; because the percent inhibition of cyclin A-associated activity was nearly complete at all time points measured, numbers are not shown in the right panel.
the mechanisms of action of the drugs will likely require direct comparisons of the two systems. However, despite the outcome of such studies, it is important, in view of the current and potential clinical usefulness of DFO, to determine the mechanism(s) of action of the drug not only in normal human T cells, but also in other normal and transformed cell types. Finally, it is noteworthy that the effects described in the present report were all observed using a dose of 10 pmol/L, a concentration that can be achieved in humans in clinical application^,'^"^ as noted above. As reported by Ajchenbaum et al," treatment of T cells with 100 pmol/L DFO resulted in dramatic inhibitory effects on expression of several cell cycle regulatory molecules, including cdk2 and, to a lesser extent, cyclin E. However, it is likely that this excess of chelating agent has other more nonspecific and toxic effects on sensitive cells. Consistent with the findings of Ajchenbaum et al,77 we had previously demonstrated"." that 100 pmol/L DFO, but not 10 pmoV L DFO, will cause an almost complete inhibition of the accumulation and phosphorylation of the p1 IORb tumor suppressor protein.
Several recent studies suggest that cell cycle models developed solely from analysis of continuously growing, transformed cell lines may not adequately reflect mechanisms involved in normal cell growth. This possibility was identified in several earlier studie~,"~~~~'~ that showed that the relative levels of certain molecules, such as some cdks and cyclins, varied greatly among various cell lines and did not reflect m e levels in n o d cells of origin. More recently, it was noted that certain complexes, comprised of cdks, cyclins, proliferating cell nuclear antigen (a component of DNA polymerase S; PCNA), and other small molecules, were altered in composition or completely disrupted in normal fibroblastic cells after virus-induced transformatrolled B-lymphoblastoid cell line with n o d lymphocytes raised the possibility that the mechanisms regulating the orderly activation of appropriate cdks was fundamentally altered in the cell line. 35 In brief, it appeared that both the cdc2-and c&-encoded kinases were activated to a high level before S-phase entry in the first cycle of cells exiting a resting (CO) state. Synthesis of the p3Pk4 protein also appeared to be aberrantly regulated in the cell lir1e.3~ Collectively, these observations, combined with a growing body of evidence showing abnormal cyclin production in a variety of tumors and tumor-derived cells,26,31-33 suggest the possibility that agents such as DFO that target pathways involved in the synthesis and/or regulation of these molecules might show useful, differential effects on normal and transformed cells, a possibility now being explored in further studies.'" tiOn.61.79 Fwhermore, our recent comparison of a growth-conFor personal use only. on November 11, 2017. by guest www.bloodjournal.org Effect of DFO on accumulation of mRNAs encoding cyclin E and cyclin A in activated human T cells. T cells were stimulated with PDB/I in the absence (lanes l, 2, and 4) or presence (lanes 3 and 51 of DFO (10 pmollL) and harvested at 0 (lanes 11, 24 (lanes 2 and  3) . or 48 (lanes 4 and 5) hours after activation. RNA was extracted, and mRNA levels for the cyclin E and cyclin A transcripts were determined by Northern blotting, as described in Materials and Methods.
Analysis for cyclin E shows a single major transcript, whereas cyclin A mRNA in human cells appears as a doublet, as indicated by the arrows. The inset at t h e bottom shows the 18s and 28s ribosomal bands after ethidium bromide-staining of the gel. After probing for cyclin A transcripts, t h e blot was stripped of cyclin A probe and retained for several weeks to permit decay of any residual radioactive material. I t was then probed for cyclin E transcripts.
As noted above, drugs that can exert profound antiproliferative effects, such as DFO, are used in many clinical situations. Often, these agents inhibit cell growth at particular points in the cell cycle, and attempts have been made to define the molecular basis for such inhibitory effects. Emerging concepts and precise knowledge of the identities and mechanisms of action of the molecules regulating major cell cycle transitions should permit identification of the targets of such drugs and, as a result, their more efficacious use in clinical applications.
